Loading…
Adenosine [A.sub.3] agonists reverse neuropathic pain via T cell-mediated production of IL-10
The [A.sub.3] adenosine receptor ([A.sub.3]AR) has emerged as a therapeutic target with [A.sub.3]AR agonists to tackle the global challenge of neuropathic pain, and investigation into its mode of action is essential for ongoing clinical development. Immune cell [A.sub.3]ARs, and their activation dur...
Saved in:
Published in: | The Journal of clinical investigation 2021-04, Vol.131 (7) |
---|---|
Main Authors: | , , , , , , , , , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | |
---|---|
cites | |
container_end_page | |
container_issue | 7 |
container_start_page | |
container_title | The Journal of clinical investigation |
container_volume | 131 |
creator | Durante, Mariaconcetta Squillace, Silvia Lauro, Filomena Giancotti, Luigino Antonio Coppi, Elisabetta Cherchi, Federica Mannelli, Lorenzo Di Cesare Ghelardini, Carla Kolar, Grant Wahlman, Carrie Opejin, Adeleye Xiao, Cuiying Reitman, Marc L Tosh, Dilip K Hawiger, Daniel Jacobson, Kenneth A Salvemini, Daniela |
description | The [A.sub.3] adenosine receptor ([A.sub.3]AR) has emerged as a therapeutic target with [A.sub.3]AR agonists to tackle the global challenge of neuropathic pain, and investigation into its mode of action is essential for ongoing clinical development. Immune cell [A.sub.3]ARs, and their activation during pathology, modulate cytokine release. Thus, the use of immune cells as a cellular substrate for the pharmacological action of [A.sub.3]AR agonists is enticing, but unknown. The present study discovered that Rag- KO mice lacking T and B cells, as compared with WT mice, are insensitive to the anti-allodynic effects of [A.sub.3]AR agonists. Similar findings were observed in interleukin-10 and interleukin-10 receptor knockout mice. Adoptive transfer of [CD4.sup.+] T cells from WT mice infiltrated the dorsal root ganglion (DRG) and restored [A.sub.3]AR agonist-mediated anti-allodynia in Rag-KO mice. [CD4.sup.+] T cells from Adora3-KO or Il10-KO mice did not. Transfer of [CD4.sup.+] T cells from WT mice, but not Il10-KO mice, into Il10- KO mice or Adora3-KO mice fully reinstated the anti-allodynic effects of [A.sub.3]AR activation. Notably, [A.sub.3]AR agonism reduced DRG neuron excitability when cocultured with [CD4.sup.+] T cells in an IL-10-dependent manner. [A.sub.3]AR action on [CD4.sup.+] T cells infiltrated in the DRG decreased phosphorylation of GluN2B-containing N-methyl-D-aspartate receptors at Tyr1472, a modification associated with regulating neuronal hypersensitivity. Our findings establish that activation of [A.sub.3]AR on [CD4.sup.+] T cells to release IL-10 is required and sufficient evidence for the use of [A.sub.3]AR agonists as therapeutics. |
doi_str_mv | 10.1172/JCI139299 |
format | article |
fullrecord | <record><control><sourceid>gale</sourceid><recordid>TN_cdi_gale_infotracmisc_A657723633</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A657723633</galeid><sourcerecordid>A657723633</sourcerecordid><originalsourceid>FETCH-LOGICAL-g289t-426c997f7f022cec05c72c0a0afe4be0d7a8b49c1905ebcae17fc26532b1ccfc3</originalsourceid><addsrcrecordid>eNqN0EtLAzEQB_AgCtbHwW8QEAQPW_PYbTbHUnxUCoKvi0jJzk62kW1SNtnix7eiBws9yBz-MPz-cxhCzjgbcq7E1f1kyqUWWu-RAS-KMiuFLPfJgDHBM61keUiOYvxgjOd5kQ_I-7hGH6LzSN_Gw9hXQ_lOTRO8iynSDtfYRaQe-y6sTFo4oCvjPF07Q58pYNtmS6ydSVjTVRfqHpILngZLp7OMsxNyYE0b8fQ3j8nLzfXz5C6bPdxOJ-NZ1ohSpywXI9BaWWWZEIDAClACmGHGYl4hq5Upq1wD16zACgxyZUGMCikqDmBBHpPzn7uNaXHuvA2pM7B0EebjUaGUkCMpNyrboRr02Jk2eLRus97ywx1-MzUuHewsXG4VNibhZ2pMH-N8-vT4f_vwum0v_tgFmjYtYmj771_Hv_ALy3Sbwg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Adenosine [A.sub.3] agonists reverse neuropathic pain via T cell-mediated production of IL-10</title><source>PubMed Central</source><source>EZB Electronic Journals Library</source><creator>Durante, Mariaconcetta ; Squillace, Silvia ; Lauro, Filomena ; Giancotti, Luigino Antonio ; Coppi, Elisabetta ; Cherchi, Federica ; Mannelli, Lorenzo Di Cesare ; Ghelardini, Carla ; Kolar, Grant ; Wahlman, Carrie ; Opejin, Adeleye ; Xiao, Cuiying ; Reitman, Marc L ; Tosh, Dilip K ; Hawiger, Daniel ; Jacobson, Kenneth A ; Salvemini, Daniela</creator><creatorcontrib>Durante, Mariaconcetta ; Squillace, Silvia ; Lauro, Filomena ; Giancotti, Luigino Antonio ; Coppi, Elisabetta ; Cherchi, Federica ; Mannelli, Lorenzo Di Cesare ; Ghelardini, Carla ; Kolar, Grant ; Wahlman, Carrie ; Opejin, Adeleye ; Xiao, Cuiying ; Reitman, Marc L ; Tosh, Dilip K ; Hawiger, Daniel ; Jacobson, Kenneth A ; Salvemini, Daniela</creatorcontrib><description>The [A.sub.3] adenosine receptor ([A.sub.3]AR) has emerged as a therapeutic target with [A.sub.3]AR agonists to tackle the global challenge of neuropathic pain, and investigation into its mode of action is essential for ongoing clinical development. Immune cell [A.sub.3]ARs, and their activation during pathology, modulate cytokine release. Thus, the use of immune cells as a cellular substrate for the pharmacological action of [A.sub.3]AR agonists is enticing, but unknown. The present study discovered that Rag- KO mice lacking T and B cells, as compared with WT mice, are insensitive to the anti-allodynic effects of [A.sub.3]AR agonists. Similar findings were observed in interleukin-10 and interleukin-10 receptor knockout mice. Adoptive transfer of [CD4.sup.+] T cells from WT mice infiltrated the dorsal root ganglion (DRG) and restored [A.sub.3]AR agonist-mediated anti-allodynia in Rag-KO mice. [CD4.sup.+] T cells from Adora3-KO or Il10-KO mice did not. Transfer of [CD4.sup.+] T cells from WT mice, but not Il10-KO mice, into Il10- KO mice or Adora3-KO mice fully reinstated the anti-allodynic effects of [A.sub.3]AR activation. Notably, [A.sub.3]AR agonism reduced DRG neuron excitability when cocultured with [CD4.sup.+] T cells in an IL-10-dependent manner. [A.sub.3]AR action on [CD4.sup.+] T cells infiltrated in the DRG decreased phosphorylation of GluN2B-containing N-methyl-D-aspartate receptors at Tyr1472, a modification associated with regulating neuronal hypersensitivity. Our findings establish that activation of [A.sub.3]AR on [CD4.sup.+] T cells to release IL-10 is required and sufficient evidence for the use of [A.sub.3]AR agonists as therapeutics.</description><identifier>ISSN: 0021-9738</identifier><identifier>EISSN: 1558-8238</identifier><identifier>DOI: 10.1172/JCI139299</identifier><language>eng</language><publisher>American Society for Clinical Investigation</publisher><subject>Care and treatment ; Cell receptors ; Development and progression ; Genetic aspects ; Health aspects ; Immune response ; Interleukins ; Peripheral nerve diseases</subject><ispartof>The Journal of clinical investigation, 2021-04, Vol.131 (7)</ispartof><rights>COPYRIGHT 2021 American Society for Clinical Investigation</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids></links><search><creatorcontrib>Durante, Mariaconcetta</creatorcontrib><creatorcontrib>Squillace, Silvia</creatorcontrib><creatorcontrib>Lauro, Filomena</creatorcontrib><creatorcontrib>Giancotti, Luigino Antonio</creatorcontrib><creatorcontrib>Coppi, Elisabetta</creatorcontrib><creatorcontrib>Cherchi, Federica</creatorcontrib><creatorcontrib>Mannelli, Lorenzo Di Cesare</creatorcontrib><creatorcontrib>Ghelardini, Carla</creatorcontrib><creatorcontrib>Kolar, Grant</creatorcontrib><creatorcontrib>Wahlman, Carrie</creatorcontrib><creatorcontrib>Opejin, Adeleye</creatorcontrib><creatorcontrib>Xiao, Cuiying</creatorcontrib><creatorcontrib>Reitman, Marc L</creatorcontrib><creatorcontrib>Tosh, Dilip K</creatorcontrib><creatorcontrib>Hawiger, Daniel</creatorcontrib><creatorcontrib>Jacobson, Kenneth A</creatorcontrib><creatorcontrib>Salvemini, Daniela</creatorcontrib><title>Adenosine [A.sub.3] agonists reverse neuropathic pain via T cell-mediated production of IL-10</title><title>The Journal of clinical investigation</title><description>The [A.sub.3] adenosine receptor ([A.sub.3]AR) has emerged as a therapeutic target with [A.sub.3]AR agonists to tackle the global challenge of neuropathic pain, and investigation into its mode of action is essential for ongoing clinical development. Immune cell [A.sub.3]ARs, and their activation during pathology, modulate cytokine release. Thus, the use of immune cells as a cellular substrate for the pharmacological action of [A.sub.3]AR agonists is enticing, but unknown. The present study discovered that Rag- KO mice lacking T and B cells, as compared with WT mice, are insensitive to the anti-allodynic effects of [A.sub.3]AR agonists. Similar findings were observed in interleukin-10 and interleukin-10 receptor knockout mice. Adoptive transfer of [CD4.sup.+] T cells from WT mice infiltrated the dorsal root ganglion (DRG) and restored [A.sub.3]AR agonist-mediated anti-allodynia in Rag-KO mice. [CD4.sup.+] T cells from Adora3-KO or Il10-KO mice did not. Transfer of [CD4.sup.+] T cells from WT mice, but not Il10-KO mice, into Il10- KO mice or Adora3-KO mice fully reinstated the anti-allodynic effects of [A.sub.3]AR activation. Notably, [A.sub.3]AR agonism reduced DRG neuron excitability when cocultured with [CD4.sup.+] T cells in an IL-10-dependent manner. [A.sub.3]AR action on [CD4.sup.+] T cells infiltrated in the DRG decreased phosphorylation of GluN2B-containing N-methyl-D-aspartate receptors at Tyr1472, a modification associated with regulating neuronal hypersensitivity. Our findings establish that activation of [A.sub.3]AR on [CD4.sup.+] T cells to release IL-10 is required and sufficient evidence for the use of [A.sub.3]AR agonists as therapeutics.</description><subject>Care and treatment</subject><subject>Cell receptors</subject><subject>Development and progression</subject><subject>Genetic aspects</subject><subject>Health aspects</subject><subject>Immune response</subject><subject>Interleukins</subject><subject>Peripheral nerve diseases</subject><issn>0021-9738</issn><issn>1558-8238</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNqN0EtLAzEQB_AgCtbHwW8QEAQPW_PYbTbHUnxUCoKvi0jJzk62kW1SNtnix7eiBws9yBz-MPz-cxhCzjgbcq7E1f1kyqUWWu-RAS-KMiuFLPfJgDHBM61keUiOYvxgjOd5kQ_I-7hGH6LzSN_Gw9hXQ_lOTRO8iynSDtfYRaQe-y6sTFo4oCvjPF07Q58pYNtmS6ydSVjTVRfqHpILngZLp7OMsxNyYE0b8fQ3j8nLzfXz5C6bPdxOJ-NZ1ohSpywXI9BaWWWZEIDAClACmGHGYl4hq5Upq1wD16zACgxyZUGMCikqDmBBHpPzn7uNaXHuvA2pM7B0EebjUaGUkCMpNyrboRr02Jk2eLRus97ywx1-MzUuHewsXG4VNibhZ2pMH-N8-vT4f_vwum0v_tgFmjYtYmj771_Hv_ALy3Sbwg</recordid><startdate>20210401</startdate><enddate>20210401</enddate><creator>Durante, Mariaconcetta</creator><creator>Squillace, Silvia</creator><creator>Lauro, Filomena</creator><creator>Giancotti, Luigino Antonio</creator><creator>Coppi, Elisabetta</creator><creator>Cherchi, Federica</creator><creator>Mannelli, Lorenzo Di Cesare</creator><creator>Ghelardini, Carla</creator><creator>Kolar, Grant</creator><creator>Wahlman, Carrie</creator><creator>Opejin, Adeleye</creator><creator>Xiao, Cuiying</creator><creator>Reitman, Marc L</creator><creator>Tosh, Dilip K</creator><creator>Hawiger, Daniel</creator><creator>Jacobson, Kenneth A</creator><creator>Salvemini, Daniela</creator><general>American Society for Clinical Investigation</general><scope>IOV</scope><scope>ISR</scope></search><sort><creationdate>20210401</creationdate><title>Adenosine [A.sub.3] agonists reverse neuropathic pain via T cell-mediated production of IL-10</title><author>Durante, Mariaconcetta ; Squillace, Silvia ; Lauro, Filomena ; Giancotti, Luigino Antonio ; Coppi, Elisabetta ; Cherchi, Federica ; Mannelli, Lorenzo Di Cesare ; Ghelardini, Carla ; Kolar, Grant ; Wahlman, Carrie ; Opejin, Adeleye ; Xiao, Cuiying ; Reitman, Marc L ; Tosh, Dilip K ; Hawiger, Daniel ; Jacobson, Kenneth A ; Salvemini, Daniela</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-g289t-426c997f7f022cec05c72c0a0afe4be0d7a8b49c1905ebcae17fc26532b1ccfc3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Care and treatment</topic><topic>Cell receptors</topic><topic>Development and progression</topic><topic>Genetic aspects</topic><topic>Health aspects</topic><topic>Immune response</topic><topic>Interleukins</topic><topic>Peripheral nerve diseases</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Durante, Mariaconcetta</creatorcontrib><creatorcontrib>Squillace, Silvia</creatorcontrib><creatorcontrib>Lauro, Filomena</creatorcontrib><creatorcontrib>Giancotti, Luigino Antonio</creatorcontrib><creatorcontrib>Coppi, Elisabetta</creatorcontrib><creatorcontrib>Cherchi, Federica</creatorcontrib><creatorcontrib>Mannelli, Lorenzo Di Cesare</creatorcontrib><creatorcontrib>Ghelardini, Carla</creatorcontrib><creatorcontrib>Kolar, Grant</creatorcontrib><creatorcontrib>Wahlman, Carrie</creatorcontrib><creatorcontrib>Opejin, Adeleye</creatorcontrib><creatorcontrib>Xiao, Cuiying</creatorcontrib><creatorcontrib>Reitman, Marc L</creatorcontrib><creatorcontrib>Tosh, Dilip K</creatorcontrib><creatorcontrib>Hawiger, Daniel</creatorcontrib><creatorcontrib>Jacobson, Kenneth A</creatorcontrib><creatorcontrib>Salvemini, Daniela</creatorcontrib><collection>Opposing Viewpoints Resource Center</collection><collection>Gale In Context: Science</collection><jtitle>The Journal of clinical investigation</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Durante, Mariaconcetta</au><au>Squillace, Silvia</au><au>Lauro, Filomena</au><au>Giancotti, Luigino Antonio</au><au>Coppi, Elisabetta</au><au>Cherchi, Federica</au><au>Mannelli, Lorenzo Di Cesare</au><au>Ghelardini, Carla</au><au>Kolar, Grant</au><au>Wahlman, Carrie</au><au>Opejin, Adeleye</au><au>Xiao, Cuiying</au><au>Reitman, Marc L</au><au>Tosh, Dilip K</au><au>Hawiger, Daniel</au><au>Jacobson, Kenneth A</au><au>Salvemini, Daniela</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Adenosine [A.sub.3] agonists reverse neuropathic pain via T cell-mediated production of IL-10</atitle><jtitle>The Journal of clinical investigation</jtitle><date>2021-04-01</date><risdate>2021</risdate><volume>131</volume><issue>7</issue><issn>0021-9738</issn><eissn>1558-8238</eissn><abstract>The [A.sub.3] adenosine receptor ([A.sub.3]AR) has emerged as a therapeutic target with [A.sub.3]AR agonists to tackle the global challenge of neuropathic pain, and investigation into its mode of action is essential for ongoing clinical development. Immune cell [A.sub.3]ARs, and their activation during pathology, modulate cytokine release. Thus, the use of immune cells as a cellular substrate for the pharmacological action of [A.sub.3]AR agonists is enticing, but unknown. The present study discovered that Rag- KO mice lacking T and B cells, as compared with WT mice, are insensitive to the anti-allodynic effects of [A.sub.3]AR agonists. Similar findings were observed in interleukin-10 and interleukin-10 receptor knockout mice. Adoptive transfer of [CD4.sup.+] T cells from WT mice infiltrated the dorsal root ganglion (DRG) and restored [A.sub.3]AR agonist-mediated anti-allodynia in Rag-KO mice. [CD4.sup.+] T cells from Adora3-KO or Il10-KO mice did not. Transfer of [CD4.sup.+] T cells from WT mice, but not Il10-KO mice, into Il10- KO mice or Adora3-KO mice fully reinstated the anti-allodynic effects of [A.sub.3]AR activation. Notably, [A.sub.3]AR agonism reduced DRG neuron excitability when cocultured with [CD4.sup.+] T cells in an IL-10-dependent manner. [A.sub.3]AR action on [CD4.sup.+] T cells infiltrated in the DRG decreased phosphorylation of GluN2B-containing N-methyl-D-aspartate receptors at Tyr1472, a modification associated with regulating neuronal hypersensitivity. Our findings establish that activation of [A.sub.3]AR on [CD4.sup.+] T cells to release IL-10 is required and sufficient evidence for the use of [A.sub.3]AR agonists as therapeutics.</abstract><pub>American Society for Clinical Investigation</pub><doi>10.1172/JCI139299</doi><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0021-9738 |
ispartof | The Journal of clinical investigation, 2021-04, Vol.131 (7) |
issn | 0021-9738 1558-8238 |
language | eng |
recordid | cdi_gale_infotracmisc_A657723633 |
source | PubMed Central; EZB Electronic Journals Library |
subjects | Care and treatment Cell receptors Development and progression Genetic aspects Health aspects Immune response Interleukins Peripheral nerve diseases |
title | Adenosine [A.sub.3] agonists reverse neuropathic pain via T cell-mediated production of IL-10 |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-18T19%3A55%3A32IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Adenosine%20%5BA.sub.3%5D%20agonists%20reverse%20neuropathic%20pain%20via%20T%20cell-mediated%20production%20of%20IL-10&rft.jtitle=The%20Journal%20of%20clinical%20investigation&rft.au=Durante,%20Mariaconcetta&rft.date=2021-04-01&rft.volume=131&rft.issue=7&rft.issn=0021-9738&rft.eissn=1558-8238&rft_id=info:doi/10.1172/JCI139299&rft_dat=%3Cgale%3EA657723633%3C/gale%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-g289t-426c997f7f022cec05c72c0a0afe4be0d7a8b49c1905ebcae17fc26532b1ccfc3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/&rft_galeid=A657723633&rfr_iscdi=true |